Dr. Viray is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
330 Brookline Ave
Boston, MA 02215Phone+1 617-667-7000
Education & Training
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2017 - 2019
Uconn School Of MedicineClass of 2016
Certifications & Licensure
MA State Medical License 2016 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 48 citationsEGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors.Pedro E.N.S. Vasconcelos, Carol Gergis, Hollis Viray, Andreas Varkaris, Masanori Fujii
JTO Clinical and Research Reports. 2020-05-13 - 3 citationsThe Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors.Ikei S Kobayashi, William Shaffer, Hollis Viray, Deepa Rangachari, Paul A VanderLaan
JTO Clinical and Research Reports. 2024-01-01 - 13 citationsexon 20 insertion mutations andmutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.Daniel Sentana-Lledo, Emmeline Academia, Hollis Viray, Deepa Rangachari, Susumu S Kobayashi
Translational Lung Cancer Research. 2023-07-31
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
